Adamas Pharmaceuticals reported -9525000 in EBIT for its first fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebit Change
Acadia Pharmaceuticals ACAD:US $ -43709000 23.06M
Aerie Pharmaceuticals AERI:US $ -31501000 2.72M
Aptinyx Inc APTX:US $ -19866000 5.58M
Biocryst Pharmaceuticals BCRX:US $ -29582000 21.8M
Flexion Therapeutics FLXN:US $ -16882000 6.26M
Glaxosmithkline GSK:US 1.96B 281M
GlaxoSmithKline GSK:LN 1.96B 281M
Gw Pharmaceuticals GWPH:US -21027000 1.78M
Heron Therapeutics HRTX:US $ -60469000 8.36M
Intra Cellular Therapies ITCI:US $ -69141060 15.92M
Marinus Pharmaceuticals MRNS:US -23485000 3.68M
Merk MRK:US $ 3930M 332M
Neurocrine Biosciences NBIX:US $ 67.8M 36.3M
Novartis NOVN:VX 3.4B 415M
Omeros OMER:US $ -24016000 6.6M
Prothena PRTA:US 27.95M 60.06M
Revance Therapeutics RVNC:US $ -70337000 325K
Teva Pharmaceutical TEVA:IT 829M 35M
Zogenix ZGNX:US $ -55431000 3.63M